ASCO 2022: Key Skin Cancer Studies

CME

Key Studies in Skin Cancer: Independent Conference Coverage of the 2022 ASCO Annual Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 29, 2022

Expiration: August 28, 2023

Allison Betof Warner
Allison Betof Warner, MD, PhD
Hussein Tawbi
Hussein Tawbi, MD

Activity

Progress
1
Course Completed

In this module, Allison Betof Warner, MD, PhD, and Hussein Tawbi, MD, PhD, examine key studies in skin cancer presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Please note that the slide thumbnails in this activity link to a capsule PowerPoint slideset for each of the studies discussed by Drs Betof Warner and Tawbi. This slideset may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with skin cancer do you provide care for in a typical month?

You are discussing treatment options with your patient who recently was diagnosed with stage IIC melanoma. During the discussion, you mention the randomized phase III KEYNOTE-716 trial of adjuvant pembrolizumab compared with placebo in patients with high-risk stage IIB/IIC melanoma. Which of the following findings from this study would you note for your patient as a consideration?

The pivotal phase II/III RELATIVITY-047 trial compared relatlimab plus nivolumab with nivolumab alone in patients with previously untreated metastatic or unresectable melanoma. According to results of a patient subgroup analysis from this study, which of the following patient subgroups derived improved response and survival outcomes with relatlimab plus nivolumab compared with nivolumab monotherapy?

A recent single-arm phase II trial of the investigational regimen of camrelizumab, apatinib, and temozolomide reported a response rate of 67% and a duration of response (DoR) of approximately 18 months in patients with which of the following subtypes of advanced melanoma?